2024 has revitalized the bacteriophage field, with over $9 Million invested into BiomX and Locus Bioscience; $24 Million dedicated by BARDA to progress bacteriophage therapies to Phase II trials; and the release of further regulatory guidelines by agencies.

The advancement to the clinic has resulted in a wealth of data available to investigate the function, genetic modification, and safety of bacteriophages. However, the lack of clarity on the pathway to the market with a sustainable and strategic commercial strategy means that biopharma companies need to rethink their business model to ensure they are sustainable.

At the 7th Bacteriophage Therapy Summit, we'll be diving into the regulatory and investment landscape for drug developers, clinical updates showing efficacy, utilizing machine learning, and developing personalized and off-the-shelf therapies to fight AMR in infectious diseases